

Durable responses with triple blockade of the DNAM-1 axis with COM701 + BMS-986207 + nivolumab in patients with platinum resistant ovarian cancer.

**Background:** Treatment options for patients with platinum resistant ovarian cancer [PROC] are limited. Immune checkpoint inhibitors (ICI) have limited activity in PROC, therefore clinical studies evaluating novel therapies are urgently needed. We have previously reported durable partial responses and a complete response with COM701 +/- BMS986207 + nivolumab<sup>1</sup>. COM701 is a novel, 1<sup>st</sup> in-class ICI binding to PVRIG, that leads to activation of T-cells. BMS-986207 is an ICI blocker of TIGIT. We report longer term follow-up showing continued durable responses in pts with PROC treated with a triple immunotherapy combination blocking the DNAM-1 axis with COM701 + BMS-986207 + nivolumab (NCT04570839).

Stephanie Gaillard, MD, PhD1, Manish Sharma, MD2, Daniel Vaena, MD3, Oladapo Yeku, MD, PhD4, Drew Rasco, MD5, Ecaterina Dumbrava6, Kyriakos P Papadopoulos, MD7, Amita Patnaik, MD8, Ryan Sullivan, MD9, Benjamin Izar, MD10, Pierre Ferre, PhD11, Eran Ophir, PhD12, Inbal Barbiro, PhD13, Gady Cojocar, PhD12, Adeboye H Adewoye, MD14 and John Moroney, MD15.

(1)Johns Hopkins, Baltimore, MD, (2)START Midwest, Grand Rapids, MI, (3)West Cancer Center and Research Institute., Memphis, TN, (4)Massachusetts General Hospital, Boston, MA, (5)START, San Antonio, TX, (6)The University of Texas MD Anderson Cancer Center, Houston, TX, (7)START Cancer Center, San Antonio, TX, (8)START San Antonio, San Antonio, TX, (9)Harvard Medical School, Massachusetts General Hospital, Needham, MA, United States, (10)Columbia University, New York, NY, (11)Compugen, Toulouse, France, (12)Compugen Ltd, Holon, Israel, (13)Compugen Ltd., Holon, Israel, Israel, (14)Compugen USA Inc., San Francisco, CA, United States, (15)University of Chicago, Chicago, IL

**Methods:** We enrolled 20 patients with PROC treated with COM701 20 mg/kg + BMS-986207 480 mg + nivolumab 480 mg IV Q4W. Primary objectives were safety/tolerability; secondary objective was preliminary antitumor activity of the combination. Key inclusion criteria: Age ≥ 18 yrs, histologically confirmed advanced malignancies and exhausted all available standard treatments. Key exclusion criteria: prior receipt of any inhibitor of PVRIG, TIGIT, or PD-(L)-1. Investigator assessed responses per RECIST v1.1, safety per CTCAE v5.0.

**Results:** No new safety signals are reported. The combination is well tolerated. There were 4/20 [20%] patients with confirmed PR and 5 pts with SD with a DCR [CR+PR+SD] 9/20 [45%], no CRs. Median [med] age 61yr, med number of prior lines of therapy - 4 [range 1-10]. Histology of patients with PR – high grade serous adenocarcinoma [3 pts], clear cell histology [1 pt]. Three pts continue study treatment at 449, 428 and 477 days, 1 pt with high grade serous adenocarcinoma was on study treatment for 222 days.

**Conclusion:** Continued durable confirmed partial responses by blocking the DNAM-1 axis with the combination of COM701 + BMS-986207 + nivolumab in pts with heavily pre-treated PROC. Additional translational data will be presented at the conference. Data extract 06/09/2023.

Study sponsored by Compugen Ltd in collaboration with Bristol Myers Squibb.

1. Moroney JA, Yeku O et al: Triple blockade of the DNAM-axis with COM701 + BMS-986207 + nivolumab demonstrates preliminary antitumor activity in patients with platinum resistant OVCA. *Annals of Oncology* (2022) 16 (suppl\_1): 100104-100104. [10.1016/j.annonc.2022.08.001](https://doi.org/10.1016/j.annonc.2022.08.001)